Company Focus
Moderna
Latest Moderna News
Biotechnology
Moderna has reported third-quarter 2024 revenues of $1.9 billion, marking a slight increase from the $1.8 billion posted in the same period in 2023. 7 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
In a filing with the US Securities and Exchange Commission (SEC), Pieris Pharmaceuticals has notified investors that Servier Laboratories is pulling the plug on the firms’ cancer collaboration. 5 July 2024
Pharmaceutical
Chennai, India-based Orchid Pharma has announced the launch of its new drug - cefepime-enmetazobactam. 4 July 2024
Biotechnology
DNA specialist INOVIO has appointed Steven Egge as chief commercial officer. 4 July 2024
Biotechnology
The global recombinant proteins market is projected to grow from $132 billion in 2023 to $203 billion by 2029, according to a recent BCC Research study. 4 July 2024
Biotechnology
US biotech Moderna has received a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. 4 July 2024
Biotechnology
British drugmaker GSK (LSE: GSK) and Germany's CureVac (Nasdaq: CVAC) have announced a restructuring of their collaboration into a new licensing agreement. 4 July 2024
Biotechnology
Shares in TRACON Pharmaceuticals have fallen by a third, after the San Diego-based firm announced the termination of work on its candidate envafolimab. 2 July 2024
Pharmaceutical
Spanish plasma-based medicines producer Grifols announced the expected launch in the first quarter of 2025 for Yimmugo. 2 July 2024
Pharmaceutical
In the USA, two New Drug Applications (NDA) for crinecerfont have been accepted by the US regulator, and will be considered under the Priority Review scheme. 1 July 2024
Biotechnology
Work on FcRn inhibition continues apace at Johnson & Johnson (NYSE: JNJ), with more success for nipocalimab. 1 July 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze